In 2021, the market for Diabetes Treatment Devices worldwide was worth $1.9 billion US dollars. AMR Group projects that the market will reach US$ 6.8 billion by 2031, growing at a CAGR of 18.6 percent between 2022 and 2031.
Industry Overview
Diabetes treatment devices refer to medical devices that are designed to help people manage their diabetes. These devices include insulin pumps, continuous glucose monitoring (CGM) systems, blood glucose meters, and insulin pens. Insulin pumps are small electronic devices that deliver insulin to the body through a catheter that is placed under the skin. CGM systems use a sensor that is placed under the skin to continuously monitor glucose levels in the interstitial fluid. Blood glucose meters are handheld devices that allow people with diabetes to check their blood glucose levels. Insulin pens are devices that are used to inject insulin.
Market Dynamics
The global diabetes treatment devices market is driven by various factors such as the increasing prevalence of diabetes worldwide, the rise in the aging population, and the growing demand for minimally invasive procedures. In addition, the increasing adoption of insulin pumps, continuous glucose monitoring systems, and self-monitoring blood glucose devices is expected to drive market growth in the coming years. On the other hand, factors such as the high cost of diabetes treatment devices, lack of awareness among people, and reimbursement issues are expected to restrain the growth of the diabetes treatment devices market. Furthermore, the emergence of innovative diabetes treatment devices such as non-invasive glucose monitoring systems and artificial pancreas systems is expected to provide significant growth opportunities for market players. The increasing focus on research and development activities to develop advanced and cost-effective diabetes treatment devices is also expected to boost market growth in the near future.
COVID Impact
The COVID-19 pandemic has had an impact on the diabetes treatment devices market in various ways. Firstly, with the disruptions caused in the global supply chains due to the lockdowns and border closures, there have been challenges in the production and distribution of diabetes treatment devices. This has led to a shortage of devices such as glucose monitoring systems and insulin pumps in some regions, which has adversely affected patient care. Secondly, the pandemic has led to a surge in demand for diabetes treatment devices as people with diabetes are considered to be at higher risk for severe illness from COVID-19. This has led to an increase in home-based diabetes management and monitoring, which has driven the demand for devices such as continuous glucose monitoring systems and insulin pumps. Thirdly, the pandemic has led to changes in the way diabetes care is delivered, with a shift towards virtual care and telemedicine. This has driven the adoption of diabetes treatment devices that can be used remotely, such as mobile apps that allow patients to track their glucose levels and communicate with their healthcare providers. Overall, the COVID-19 pandemic has had a mixed impact on the diabetes treatment devices market, with challenges in the supply chain and production being offset by an increase in demand for home-based diabetes management and remote monitoring devices.
Regional Trend
The global market for diabetes treatment devices is analyzed on a regional basis to understand the market dynamics and trends across different regions of the world. The major regions analyzed in the report include North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.
North America is the largest market for diabetes treatment devices due to the high prevalence of diabetes in the region, favorable government initiatives, and the presence of major market players. Europe is the second-largest market, with a significant number of people suffering from diabetes and an increasing awareness of the disease and its management.
The Asia-Pacific region is expected to witness the fastest growth during the forecast period, owing to the increasing prevalence of diabetes, growing healthcare expenditure, and improving healthcare infrastructure. The rising population and changing lifestyles are contributing to the increasing burden of diabetes in the region. Latin America and the Middle East & Africa are also expected to experience significant growth due to the rising prevalence of diabetes, increasing awareness, and improving healthcare infrastructure. However, the lack of awareness and poor healthcare facilities in some countries may hinder market growth in these regions.
Competitive Landscape
The diabetes treatment devices market is highly competitive with a large number of players operating in the market. Some of the key players in the market include Medtronic, Dexcom, Roche, Abbott, Insulet, Tandem Diabetes Care, Ypsomed, Ascensia Diabetes Care, Becton, Dickinson and Company, and Sanofi, among others. These players focus on various strategies such as mergers and acquisitions, partnerships and collaborations, and new product launches to strengthen their market position. For instance, in 2020, Medtronic acquired Companion Medical, a manufacturer of the InPen, an insulin pen that transmits data to a connected device. This acquisition helped Medtronic expand its portfolio of smart insulin pens and mobile app solutions. Similarly, in 2019, Roche acquired mySugr, a digital health company that provides diabetes management solutions. This acquisition helped Roche strengthen its digital health offerings and expand its presence in the diabetes market. Moreover, companies are also investing in research and development activities to introduce innovative diabetes treatment devices in the market. For instance, in 2021, Dexcom announced the launch of its next-generation continuous glucose monitoring (CGM) system, the Dexcom G7, which features a smaller, disposable sensor and a simpler transmitter. This launch helped Dexcom strengthen its position in the CGM market.
Market Segmentation
The diabetes treatment devices market can be segmented based on product type, end-user, and region.
Based on product type, the market can be segmented into:
Blood glucose monitoring devices: includes self-monitoring blood glucose (SMBG) devices, continuous glucose monitoring (CGM) systems, and flash glucose monitoring (FGM) systems.
Insulin delivery devices: includes insulin pens, insulin pumps, insulin syringes, and insulin jet injectors.

Based on end-user, the market can be segmented into:
Hospitals and clinics
Homecare settings
Diagnostic centers and research institutes